#EMD Serono

Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially a...

The first of a two-part look at the top treatment news of 2010.

Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from...

FDA advisory panel is convening this week to decide whether to recommend approval of Egrifta, a belly fat-busting drug.

A U.S. Food and Drug Administration independent advisory committee is set to review Montreal-based Theratechnologies’ New Drug Application..

Montreal-based Theratechnologies announced yesterday that the U.S. Food and Drug Administration (FDA) will reschedule its meeting with...

People with private health insurance using Serostim can now save up to $200 per month on their monthly co-payments.

If approved, tesamorelin will be sold in the United States by EMD Serono.

A new non-nuke, the apparent cure of an HIV-positive patient receiving a bone marrow transplant and the possibility of earlier...

The company also confirmed a proposed deal with EMD Serono to sell the drug in the United States once it is approved.

Theratechnologies announced today that it has sold the rights to sell the experimental lipodystrophy drug tesamorelin in the United StatesR...

The drug takers and insurance companies that paid for the injectable treatments are about to recoup some of their money.

Swiss drug maker Serono Laboratories agreed to pay $704 million and pleaded guilty

In a chilling first-ever, counterfeiters strike at a U.S. AIDS drug. Julie Hantman asks whodunit.

Treatment options for fat-gone-haywire

A tip on getting your insurer to pay for pricey drugs